Galmed Pharmaceuticals Ltd expected to post a loss of 30  cents a share - Earnings Preview

Eocene

29/04/2022 19:17

* Galmed Pharmaceuticals Ltd  GLMD.OQ   GLMD.O  is expected
to show no change in quarterly revenue when it reports 
results on May 2. 
    * ​Refinitiv's mean analyst estimate for Galmed
Pharmaceuticals
Ltd is for a loss of 30 cents per share. For the same quarter
last year, the company reported a loss of 48 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Galmed
Pharmaceuticals Ltd is $19​, above​ its last closing price
of $1.53. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.37       -0.36      -0.31     Beat    13.4
 Jun. 30 2021  -0.41       -0.38      -0.33     Beat    13.6
 Mar. 31 2021  -0.42       -0.38      -0.38     Met     1.3​
 Dec. 31 2020  -0.35       -0.36      -0.48     Missed  -31.9
 ​​Sep.        -0.29       -0.30      -0.32     Missed  -6.7
 30 2020                                                
 Jun. 30 2020  -0.31       -0.32      -0.26     Beat    18.4​
 Mar. 31 2020  -0.35       -0.37      -0.29     Beat    20.8
 Dec. 31 2019  -0.27       -0.34      -0.39     Missed  -13.2
 This summary was machine generated April 29 at 18:17 GMT.  All
figures in US dollars  unless otherwise stated